Vendor Intelligence Report: Alimo Peptide

Published 3 Jul 2026. 20-page investigative report on who is behind Alimo Peptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Alimo Peptide is a narrow, uneven test record attached to a messy operating footprint. Across 8 Finnrick lab tests, Alimo shows 4 pass / 4 fail, for an overall pass rate of 50%. The signal is product-specific: Tirzepatide is the less weak of the two tested lines but has severe dose-variance evidence, while Retatrutide carries the clearer avoid signal because the record includes a product-identity failure.

The non-lab picture does not simplify the read. Alimo is listed to Finnrick as US, yet its public market identity points to Shanghai Alimopeptide Biotechnology Co., LTD / 上海阿利莫肽生物科技有限公司, with the buyer-facing operator alias Eric. The canonical domain is offline and non-resolving, and the current buyer path runs through a public Google Document, Telegram or WhatsApp, email, a Discord reference, and cryptocurrency-only payment.

Forum evidence shows a vendor that did not simply disappear: GLP-1 Forum activity runs through late 2025, and an Anabolex thread presents the operation as an Approved China Supplier with pricing, COA links, warehouse claims, and a customs-reship promise. But that market presence sits beside a complaint record describing inconsistent T60 Tirzepatide, alleged ghosting of customer-funded test groups, and weak make-good terms. Ratings also fall under stricter grading, pointing less to a simple purity story than to identity and fill-control reliability.

Inside the full report:

  • Per-product Finnrick pass/fail analysis and methodology-divergence charts for Tirzepatide and Retatrutide
  • Sample-level discussion of Tirzepatide overfill and the Retatrutide identity failure
  • Wayback and DNS review of alimopeptide.com, including the shift from storefront to Google Document sales
  • Operating-identity dossier covering Shanghai Alimopeptide Biotechnology Co., LTD, forum handles, emails, and messaging rails
  • GLP-1 Forum and Anabolex evidence, including complaint handling, COA-link context, and warehouse claims
  • Material risk matrix covering product identity, dose variance, recourse risk, shipping reliability, and channel authentication

Risk assessment

  • Retatrutide product-identity failure risk — high: Retatrutide: 3 tests with 1 pass / 2 fail and a 74.82% rating; field/Finnrick record includes a vial labeled 15mg reported as containing no Retatrutide.
  • Tirzepatide dose-variance risk — high: Tirzepatide: 5 tests with 3 pass / 2 fail and a 75.95% rating; sample-level evidence includes severe overfills up to +78.7%.
  • Dispute-resolution and buyer-recourse risk — high: Forum complaint alleges Eric ghosted two T60 test groups and offered 17% credit or T10 with buyers paying shipping/testing again; crypto-only payment removes chargeback leverage.
  • Infrastructure and channel-authentication risk — medium: alimopeptide.com is offline/non-resolving; sales rely on a public Google Doc plus Telegram/WhatsApp/email/Discord references, with no signed official-channel list or anti-counterfeit system found.
  • Shipping reliability risk — medium: Forum reports described February/March 2025 orders still unresolved by April while the vendor continued accepting new orders.